Literature DB >> 15592323

A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.

Tatsuki Fukami1, Miki Nakajima, Ryoko Yoshida, Yuki Tsuchiya, Yuto Fujiki, Miki Katoh, Howard L McLeod, Tsuyoshi Yokoi.   

Abstract

Cytochrome P450 (CYP) 2A6 is a major CYP responsible for the metabolism of nicotine and coumarin in humans. We identified a novel allele, designated CYP2A6*17 , which contains A51G (exon 1), C209T (intron 1), G1779A (exon 3), C4489T (intron 6), G5065A (V365M, exon 7), G5163A (intron 7), C5717T (exon 8), and A5825G (intron 8). We developed a genotyping method by polymerase chain reaction-restriction fragment length polymorphism for the CYP2A6*17 allele, targeting the G5065A mutation. The allele frequency in black subjects (n = 96) was 9.4% (95% confidence interval [CI], 5.3%-13.5%). The allele was not found in white subjects (95% CI, 0%-0.9%; n = 163), Japanese subjects (95% CI, 0%-1.6%; n = 92), and Korean subjects (95% CI, 0%-0.7%; n = 209). To examine the effects of the amino acid change in the CYP2A6*17 allele on the enzymatic activity, we expressed a wild-type or variant (V365M) CYP2A6 together with NADPH-CYP reductase in Escherichia coli . For coumarin 7-hydroxylation, the apparent Michaelis-Menten constant value of variant CYP2A6 (1.06 +/- 0.11 micromol/L) was significantly (P < .005) higher than that of wild type (0.60 +/- 0.05 micromol/L). The maximum velocity values of the wild-type and variant CYP2A6 were 0.61 +/- 0.06 and 0.64 +/- 0.07 pmol . min -1 . pmol -1 CYP, respectively. For nicotine C -oxidation, the apparent Michaelis-Menten constant values of the wild-type or variant CYP2A6 were 31.6 +/- 2.9 micromol/L and 31.3 +/- 3.1 micromol/L, respectively. The maximum velocity value of variant CYP2A6 (0.72 +/- 0.21 pmol . min -1 . pmol -1 CYP) was significantly (P < .05) lower than that of the wild type (1.80 +/- 0.42 pmol . min -1 . pmol -1 CYP). Thus the intrinsic clearance values for coumarin 7-hydroxylation and nicotine C -oxidation by the variant were both significantly (P < .05) decreased to 40% to 60% compared with the wild type. Furthermore, cotinine/nicotine ratios after 1 piece of nicotine gum was chewed, used as an index of in vivo nicotine metabolism, were significantly (P < .05) decreased in heterozygotes of the CYP2A6*17 allele (5.4 +/- 2.7, n = 12) compared with homozygotes of the wild type (11.5 +/- 10.5, n = 37). A subject with CYP2A6*17 / CYP2A6*17 revealed the lowest cotinine/nicotine ratio (1.8). We found a novel allele in black subjects that affects the nicotine metabolism in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592323     DOI: 10.1016/j.clpt.2004.08.014

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

2.  CYP2A6 genetic variation and dexmedetomidine disposition.

Authors:  Utkarsh Kohli; Pratik Pandharipande; Mordechai Muszkat; Gbenga G Sofowora; Eitan A Friedman; Mika Scheinin; Alastair J J Wood; E Wesley Ely; Rachel F Tyndale; Leena Choi; C Michael Stein; Daniel Kurnik
Journal:  Eur J Clin Pharmacol       Date:  2012-01-21       Impact factor: 2.953

3.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Authors:  Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

Review 4.  Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.

Authors:  Panjasaram Naidoo; Vasudevan V Chetty; Manoranjenni Chetty
Journal:  Eur J Clin Pharmacol       Date:  2014-01-05       Impact factor: 2.953

5.  Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Authors:  Meghan J Chenoweth; Jennifer J Ware; Andy Z X Zhu; Christopher B Cole; Lisa Sanderson Cox; Nikki Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Robert A Schnoll; Larry W Hawk; Paul M Cinciripini; Tony P George; Caryn Lerman; Joanne Knight; Rachel F Tyndale
Journal:  Addiction       Date:  2017-11-02       Impact factor: 6.526

6.  Pharmacogenetics in Ghana: reviewing the evidence.

Authors:  W Kudzi; G O Adjei; D Ofori-Adjei; A N O Dodoo
Journal:  Ghana Med J       Date:  2011-06

7.  The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Authors:  Andy Z X Zhu; Caroline C Renner; Dorothy K Hatsukami; Gary E Swan; Caryn Lerman; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-31       Impact factor: 4.254

Review 8.  Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

9.  CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W Sagoe; Naser L Rzek; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

10.  Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Authors:  David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court
Journal:  J Antimicrob Chemother       Date:  2014-04-11       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.